HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Leone, F. Articles by Lloyd, D.H. Search for Related Content PubMed PubMed Citation Articles by Leone, F. Articles by Lloyd, D.H.

The Use of Trilostane for the Treatment of Alopecia X in Alaskan Malamutes

From the Clinica Veterinaria Adriatica (Leone), Senigallia, SS Adriatica Nord 50/1-2, 60019 Senigallia, Italy; The Department of Clinical Studies (Cerundolo), School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6010; Ambulatorio Veterinario Associato (Vercelli), Corso Traiano 99d, 10135 Torino, Italy; and the Department of Veterinary Clinical Sciences (Lloyd), Royal Veterinary College, University of London, North Mymms, Hatfield, Herts, AL9 7TA, England.

Address all correspondence to Dr. Cerundolo.

Three Alaskan malamutes with hair loss and slightly elevated blood concentrations of 17-hydroxyprogesterone after stimulation with adrenocorticotropic hormone (ACTH) were treated with trilostane. Trilostane, an inhibitor of 3 ß-hydroxysteroid dehydrogenase, was given twice daily at a dose of 3.0 to 3.6 mg/kg per day orally for 4 to 6 months. Routine ACTH stimulation tests were performed over 8 months to evaluate the degree of adrenal function suppression. Treatment with trilostane led to complete hair regrowth in all three dogs within 6 months. No adverse effects associated with trilostane were recognized.